Patient‐reported outcomes from a single‐centre prospective post‐marketing study on Collagenase Clostridium Histolyticum injections for Peyronie's disease
| Autor: | Dana A. Ohl, Susanne A. Quallich, Frederik M. Jacobsen, Bahaa S. Malaeb, Christian Fuglesang S Jensen, Jens Sønksen, Mikkel Fode |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Urology Penile Induration 030232 urology & nephrology Injections Intralesional 03 medical and health sciences 0302 clinical medicine Endocrinology Collagenase clostridium histolyticum Intralesional injections Internal medicine medicine Humans Patient Reported Outcome Measures Prospective Studies Marketing Baseline values 030219 obstetrics & reproductive medicine business.industry General Medicine medicine.disease humanities Single centre Microbial Collagenase Treatment Outcome Penile curvature Peyronie's disease business After treatment Penis medicine.drug |
| Zdroj: | Andrologia. 52 |
| ISSN: | 1439-0272 0303-4569 |
| DOI: | 10.1111/and.13733 |
| Popis: | The aim of this study was to evaluate patient-reported outcomes of Collagenase Clostridium Histolyticum (CCHi) for Peyronie's Disease. Patients treated with 2-4 cycles of CCHi between 01/2016 and 08/2018 were asked to fill out the "bother domain" of the Peyronie's Disease Questionnaire (PDQ) at scheduled appointments for injections. CCHi cycles involved two injections (0.58 mg) separated by 48-72 hr. During the study, 34 patients were treated, seven patients were excluded due to incomplete baseline values. Mean (standard deviation) PDQ bother domain baseline score was 11.1 (2.6). ANOVA demonstrated statistically significant effects of injections (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|